New Afrezza Direct Purchase Program Launched
January 16, 2019 – MannKind Corporation has announced the launch of a new Afrezza® (insulin human) inhalation powder direct purchase program for eligible patients. Afrezza is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients who have diabetes mellitus.
The Afrezza Patient Direct Program streamlines distribution of the medication, allowing MannKind to pass on savings to cash-paying uninsured and underinsured patients, according to a press release. During the month of January, the first 1,000 eligible patients to sign up for the program at www.insulinsavings.com could lock in $4/month pricing for Afrezza for up to one year.
In addition to the cash program, MannKind has launched an enhanced copay savings card program that allows commercially insured patients to obtain Afrezza for as low as $15 per month. Patients can register for the program at afrezza.copaysavingsprogram.com.
Afrezza first received FDA approval in 2014. Recommended dosing depends on individual patient factors, including treatment history and concomitant use of subcutaneously administered insulin. A black box warning cautions that Afrezza may cause acute bronchospasm in patients who have chronic obstructive pulmonary disorder (COPD), and is contraindicated in patients who have asthma and COPD.